Tackling targets long considered undruggable, clinical-stage biopharmaceutical company Parabilis Medicines has raised a substantial $670.0M in new capital. The firm is pioneering a new class of alpha-helical peptides, Helicons, designed to modulate intracellular proteins for serious diseases.
Its lead investigational medicine, zolucatetide, is the first direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is currently being evaluated in clinical trials for various Wnt/β-catenin-driven conditions, including desmoid tumors and familial adenomatous polyposis.













.png&w=3840&q=75)